[68Ga]Ga-DWJ155

Phase 1

Novartis

[68Ga]Ga-DWJ155 is one of 36 therapeutic programs targeting Breast Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Breast NeoplasmsRecruiting

Breast NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

39 competitors in Breast Neoplasms

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

3 2

Keytruda

Merck & Co.

Phase 3

2 3

Abraxane

Bristol-Myers Squibb

Phase 3

2 4

Kisqali

Novartis

Phase 3

2 5

Ibrance

Pfizer

Phase 3

2 6

Verzenio

Eli Lilly

Phase 3

2 7

Adriamycin

Pfizer

Phase 3

1 8

Ellence

Pfizer

Phase 3

1 9

Lynparza

AstraZeneca

Phase 3

1 10

Gemzar

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Breast Neoplasms

NCT07117214

Clinical

Trials by Indication[1]

Breast Neoplasms1 trial

A Phase I, Open Label First in Human Study to Evaluate the Imaging Performance, Safety, Biodistribution and Pharmacokinetics of [68Ga]Ga-DWJ155 in Adult Patients With Advanced Breast Cancer and Advanced NSCLC

Recruiting· Novartis logo

Novartis·Phase 1·NCT07117214·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [68Ga]Ga-DWJ155. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [68Ga]Ga-DWJ155. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

[68Ga]Ga-DWJ155

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Breast Neoplasms1 trial

References

Drug Info

Quick Facts

Related News